Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) Stock-based compensation expense from the issuance of stock options and RSUs in fiscal 2009, 2008 and 2007 is as follows:
## Table 0 ##
Stock-based compensation expense related to stock options was $13,829, $13,968, and $4,725.
Stock compensation expense related to the fair value of RSUs was $19,110, $11,696, and 1,379 in fiscal years 2009, 2008 and 2007, respectively.
The related tax benefit recorded in the consolidated statements of operations was $9,755, $8,365 and $1,715 in fiscal years 2009, 2008 and 2007, respectively.
At September 26, 2009, there was $31,966 and $33,026 of unrecognized compensation expense related to stock options and RSUs, respectively, to be recognized over a weighted average period of 3.5 years and 2.3 years, respectively.
Included in stock-based compensation expense for fiscal 2008 was $2,662 as a result of the acceleration of vesting for certain outstanding Hologic stock options upon the close of the merger with Cytyc.
The original terms of these employee stock options provided for acceleration of vesting upon a change of control.
In addition, stock-based compensation expense includes a total of $3,512 related to option modifications during fiscal 2008.
During this period, the Company recorded $768 related to a modification of certain options to extend the period of time to exercise upon termination from 90 days to August 31, 2009 upon termination of the Company’s Chairman of the Board of Directors (See Note 2).
The Company also recorded $2,264 of stock-based compensation as a result of a modification of certain Hologic stock options in connection with the merger with Cytyc Agreement in May 2007.
The modification provided for acceleration of vesting of the unvested options upon a termination as a result of a change of control, as well as an extension of the period to exercise vested options from 90 days to December 31, 2009, which occurred upon the close of the merger with Cytyc.
Additionally, stock-based compensation expense included $480 related to certain former Third Wave executives who were terminated.
In fiscal 2008, stock-based compensation included $570 as a result of the acceleration of vesting for certain outstanding Hologic restricted stock units upon the close of the merger with Cytyc.
The original terms of these restricted stock units provided for acceleration of vesting upon a change of control.
Fiscal 2008 stock-based compensation also included $1,174 related to the acceleration of certain restricted stock units related to a separation agreement with the Company’s Chairman of the Board of Directors.
Prior to the close of the merger the Board of Directors of both Hologic and Cytyc approved a modification to certain outstanding equity awards for Cytyc employees.
The modification provided for the acceleration of vesting upon the close of Merger for those awards that did not provide for acceleration upon a change of control as part of the original terms of the award.
This modification was made so that the Company would not incur stock based compensation charges that it otherwise would have if the awards had continued to vest under their original terms.
Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) Option Exchange Program On December 22, 2008, the Board of Directors approved, subject to stockholder approval, a stock option exchange program (the “Option Exchange Program”).
The Option Exchange Program was approved at the Annual Meeting of Stockholders held on March 4, 2009.
The Option Exchange Program permitted eligible employees to exchange their outstanding options issued on January 16, 2008 at an exercise price per share of $33.31 for a lesser number of new options (“New Options”), with such number of New Options issuable upon exchange calculated pursuant to an exchange ratio based on the original exercise price of the surrendered option.
The exchange offer expired on April 5, 2009.
Pursuant to the Option Exchange Program, the New Options have an exercise price of $14.87, which is 110% of the last reported closing sales price of the Company’s common stock as of the date of the new grant, which was April 5, 2009.
The total number of stock options eligible to be exchanged of 784 was exchanged for 406 New Options.
On the date of exchange, the estimated fair value of the New Options approximated the estimated fair value of the exchanged stock options calculated immediately prior to the exchange.
As such, there is no incremental fair value of the New Options, and the Company will not record additional compensation expense related to the exchange.
The Company will continue to recognize the remaining compensation expense related to the exchanged options over the remaining vesting period of the original options.
The New Options become exercisable over a period of four years, with 25% vesting on the first anniversary of the date the New Options were granted and 25% vesting on each anniversary thereafter, so long as the option holder continues to be employed by the Company.
Share Based Payment Activity The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 26, 2009:
## Table 1 ##
(1) This represents the number of vested stock options as of September 26, 2009 plus the unvested outstanding options at September 26, 2009 expected to vest in the future, adjusted for estimated forfeitures.
During fiscal 2008 and 2007, the total intrinsic value of options exercised (i. e. , the difference between the market price on the date of exercise and the price paid by the employee to exercise the options) was $196,960 and $63,477, respectively.
Table of Contents Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) A summary of the Company’s Restricted Stock Units activity during the year September 26, 2009 is presented below:
## Table 2 ##
The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy minimum statutory tax withholding requirements.
During fiscal 2009, 2008 and 2007 the total fair value of RSUs vested was $5,014, $2,009 and $0, respectively.
Employee Stock Purchase Plan At the Company’s March 11, 2008 Annual Meeting of Stockholders, the Company’s 2008 Employee Stock Purchase Plan (the “ESPP”) was approved.
The plan meets the criteria set forth in ASC 718’s definition of a non-compensatory plan and does not give rise to stock-based compensation expense.
Employees who have completed three consecutive months, or two years, whether or not consecutive, of employment with the Company or any of its participating subsidiaries are eligible to participate in the ESPP.
The ESPP plan period is semi-annual and allows participants to purchase the Company’s common stock at 95% of the closing price of the stock on the last day of the plan period.
A total of 400 shares may be issued under the ESPP.
During fiscal 2009, the Company issued 121 shares under the ESPP.10.
Profit Sharing 401(k) Plan The Company has a qualified profit sharing plan covering substantially all of its employees.
Contributions to the plan are at the discretion of the Company’s Board of Directors.
The Company made contributions of $5,725, $5,305 and $1,572 for fiscal years 2009, 2008 and 2007, respectively.11.
Supplemental Executive Retirement Plan Effective March 15, 2006, the Company adopted a SERP to provide non-qualified retirement benefits to a select group of executive officers, senior management and highly compensated employees of the Company.
Eligible employees may elect to contribute up to 75% of their annual base salary and 100% of their annual bonus to the SERP and such employee contributions are 100% vested.
In addition, the Company may elect to make annual discretionary contributions on behalf of participants in the SERP.
Each Company contribution is subject to a three year vesting schedule, such that each contribution vests one third annually.
Employee contributions are recorded within accrued expenses in the Consolidated Balance Sheets.
Upon enrollment into the SERP, employees make investment elections for both their voluntary contributions and discretionary contributions, if any, made by the Company.
Earnings and losses on contributions based on these investment elections are recorded as a component of compensation expense in the period earned.
## Table 3 ##
(1) All share and per share data have been retroactively restated to reflect the 2-for-1 stock splits effected on November 30, 2005 and April 2, 2008.
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and the information described under the caption “Risk Factors” included elsewhere in this report.
OVERVIEW We are a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women.
Our core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health.
Historically, we have developed, manufactured and marketed products focused on mammography, breast care and osteoporosis assessment.
We have historically focused our resources on developing systems and subsystems offering superior image quality and diagnostic accuracy, which has enabled us to capture significant market share and customer loyalty, despite the presence of large competitors.
Our merger with Cytyc in the first quarter of fiscal 2008 enabled us to benefit from Cytyc’s strengths in the fields of obstetrics, gynecology, radiation oncology and minimally invasive surgery.
Our breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (“CAD”), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products.
We have also developed a new breast imaging platform, “Dimensions”, which utilizes a new technology, tomosynthesis, to produce three dimensional (“3D”) images, as well as conventional two dimensional (“2D”) full field digital mammography (FFDM) images.
In the U. S. , our Dimensions product has been approved by the FDA for providing conventional 2D images, and we are conducting further clinical trials to support our PMA application for the 3D configuration.
Our Dimensions platform received CE mark approval in Europe in fiscal 2008 and Canadian registration in March 2009, both for 2D and 3D modes of imaging.
Currently, we cannot determine the timing of FDA approval for our 3D configuration, if at all.
We also sell breast biopsy products, and within our breast brachytherapy products is our MammoSite System, which

<table><tr><td></td><td>  2009</td><td> 2008</td><td>  2007</td></tr><tr><td>Cost of revenues</td><td>$3,522</td><td>$2,293</td><td>$695</td></tr><tr><td>Research and development</td><td>3,960</td><td>2,806</td><td>828</td></tr><tr><td>Selling and marketing</td><td>5,161</td><td>3,487</td><td>602</td></tr><tr><td>General and administrative</td><td>20,296</td><td>15,137</td><td>3,979</td></tr><tr><td>Restructuring charge</td><td>—</td><td>1,941</td><td>—</td></tr><tr><td></td><td>$32,939</td><td>$25,664</td><td>$6,104</td></tr></table>
<table><tr><td></td><td>Number of Shares</td><td> Weighted- Average Exercise Price</td><td> Weighted- Average Remaining Contractual Life in Year</td><td> Aggregate Intrinsic Value</td></tr><tr><td>Options outstanding at September 27, 2008</td><td>14,493</td><td></td><td></td><td></td></tr><tr><td>Granted</td><td>3,007</td><td>$14.43</td><td></td><td></td></tr><tr><td>Cancelled/forfeited</td><td>-1,263</td><td>19.51</td><td></td><td></td></tr><tr><td>Net effect of option cancellation/regrant</td><td>-378</td><td>33.31</td><td></td><td></td></tr><tr><td>Exercised</td><td>-1,306</td><td>7.19</td><td></td><td>$10,525</td></tr><tr><td>Options outstanding at September 26, 2009</td><td>14,553</td><td>$16.42</td><td>4.91</td><td>$47,630</td></tr><tr><td>Options exercisable at September 26, 2009</td><td>9,531</td><td>$14.60</td><td>4.23</td><td>$41,310</td></tr><tr><td>Options vested and expected to vest at September 26, 2009 -1</td><td>14,068</td><td>$16.36</td><td>4.87</td><td>$46,946</td></tr></table>
<table><tr><td>Non-vested Shares</td><td>Number of Shares</td><td>Weighted-Average Grant-Date Fair Value</td></tr><tr><td>Non-vested at September 27, 2008</td><td>1,461</td><td>$31.23</td></tr><tr><td>Granted.</td><td>1,669</td><td>14.46</td></tr><tr><td>Vested</td><td>-210</td><td>23.87</td></tr><tr><td>Forfeited</td><td>-150</td><td>23.44</td></tr><tr><td>Non-vested at September 26, 2009</td><td>2,770</td><td>$21.96</td></tr></table>
<table><tr><td></td><td colspan="5"> Fiscal Years Ended</td></tr><tr><td></td><td>September 26, 2009</td><td>September 27, 2008</td><td> September 29, 2007</td><td> September 30, 2006</td><td> September 24, 2005</td></tr><tr><td></td><td colspan="5"> (In thousands, except per share data)</td></tr><tr><td>Basic net (loss) income per common share (1)</td><td>$-8.48</td><td>$-1.57</td><td>$0.88</td><td>$0.29</td><td>$0.33</td></tr><tr><td>Diluted net (loss) income per common share (1)</td><td>$-8.48</td><td>$-1.57</td><td>$0.86</td><td>$0.28</td><td>$0.31</td></tr><tr><td>Weighted average number of common shares outstanding -1:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Basic</td><td>256,545</td><td>245,968</td><td>106,873</td><td>93,025</td><td>85,648</td></tr><tr><td>Diluted</td><td>256,545</td><td>245,968</td><td>109,669</td><td>97,240</td><td>90,252</td></tr><tr><td> <i>Consolidated Balance Sheet Data</i></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Working capital</td><td>$492,226</td><td>$352,703</td><td>$220,568</td><td>$123,493</td><td>$172,615</td></tr><tr><td>Total assets</td><td>5,689,828</td><td>8,134,632</td><td>1,066,349</td><td>856,205</td><td>279,839</td></tr><tr><td>Line of credit</td><td>—</td><td>—</td><td>—</td><td>55,000</td><td>—</td></tr><tr><td>Long-term debt</td><td>1,864,955</td><td>2,162,420</td><td>9,222</td><td>6,163</td><td>—</td></tr><tr><td>Total stockholders’ equity</td><td>2,512,715</td><td>4,642,269</td><td>805,723</td><td>605,750</td><td>217,834</td></tr></table>

Question: based on the fair value of the grant , how much money did the company lose when some of their grants were forfeited .